Comparative Pharmacology
Head-to-head clinical analysis: ENFLONSIA versus ENFLURANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENFLONSIA versus ENFLURANE.
ENFLONSIA vs ENFLURANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENFLONSIA is a synthetic opioid that acts as a full agonist at mu-opioid receptors, producing analgesia, sedation, and euphoria. It also has weak activity at kappa and delta opioid receptors.
Enflurane is a volatile halogenated ether that potentiates GABA-A receptor activity, inhibits NMDA receptors, and enhances glycine receptor function, leading to generalized central nervous system depression and anesthesia.
10 mg orally twice daily for 12 weeks; if tolerated and response inadequate, may increase to 20 mg twice daily.
Induction: 0.5-4.5% inspired concentration; Maintenance: 0.5-3% inspired concentration with oxygen/nitrous oxide; via inhalation.
None Documented
None Documented
Clinical Note
moderateEnflurane + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Enflurane is combined with Fluticasone propionate."
Clinical Note
moderateEnflurane + Methylphenidate
"Enflurane may increase the hypertensive activities of Methylphenidate."
Clinical Note
moderateEnflurane + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Enflurane."
Clinical Note
moderateEnflurane + Clemastine
Terminal half-life 12-16 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment.
Terminal elimination half-life is approximately 4-8 hours in adults; context: prolonged with obesity due to high lipid solubility and storage in adipose tissue.
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal elimination as metabolites.
Primarily eliminated by pulmonary excretion as unchanged drug (>90%); less than 5% is metabolized via CYP2E1 to fluoride ions and other metabolites, which are renally excreted.
Category C
Category C
Inhalational Anesthetic
Inhalational Anesthetic
"The risk or severity of adverse effects can be increased when Enflurane is combined with Clemastine."